莫西沙星溶液雾化吸入治疗COPD合并呼吸衰竭的疗效

Curative Effect of Moxifloxacin Solution Atomization Inhalation in Treatment COPD Combined with Respiratory Failure

目的:探讨莫西沙星溶液雾化吸入治疗慢性阻塞性肺病(COPD)合并呼吸衰竭的疗效。方法:选择2014年5月~2016年5月于我院就诊的94例COPD合并呼吸衰竭患者,参照抽签法分为对照组(n=47)与研究组(n=47),对照组行常规治疗,研究组基于对照组加用莫西沙星溶液雾化吸入治疗。比较两组的疗效,血清肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)、白细胞介素10(IL-10)水平、肌酸磷酸激酶(CK)、谷草转氨酶(AST)水平,血氧分压(PaO_2)、二氧化碳分压(PaCO_2),APACHEⅡ评分和不良反应的发生情况。结果:治疗后,研究组的总有效率显著高于对照组(P<0.05),血清TNF-α、CRP、CK、LDH、AST、PaCO_2、APACHEⅡ评分均明显低于对照组(P<0.05),血清IL-10、PaO_2水平均高于对照组(P<0.05)。两组不良反应的发生情况比较差异无统计学意义(P>0.05)。结论:莫西沙星溶液雾化吸入治疗COPD合并呼吸衰竭的疗效确切,可能与其有效抑制炎症反应,改善呼吸有关。

Objective： To research the curative effect of moxifloxacin solution atomization inhalation in the treatment of chronic obstructive pulmonary disease （COPD） combined with respiratory failure. Methods： 94 cases of COPD patients combined with respirato- ry failure from May 2014 to May 2016 were selected and divided into the control group（n=47） and the research group （n=47） acording to the lottery method, the control group received routine treatment, while the research group was treated based on the control group with moxifloxacin solution inhalation treatment. The curative effect, serum tumor necrosis factor-et（TNF-ct）, c-reactive protein （CRP） and in- terleukin 10 （IL-10）, creatine phosphokinase （CK）, aspertate aminotransferase （AST） levels, the blood oxygen partial pressure （PaO2）, CO2 partial pressure （PaCO2）, APACHE II score and occurrence of adverse reactions were compared between two groups. Results： After treatment, the total effective rate of research group was higher than that of the control group （P〈0.05）. The serum levels of TNF alpha, CRP, PaCO2, CK, AST, APACHE Ⅱ score of research group were evidently lower than those of the control group （P〈0.05）. The serum levels of IL-10, PaO2 of research group were evident higher than those of the control group （P〈0.05）. The occurrence of adverse reactions showed no differences between the two groups （P〉0.05）. Conclusion： Moxifloxacin solution atomization inhalation was effective in the treatment of COPD combined with respiratory failure, which might be related to the inhibition of inflammatory response, and improvment of breath.